Opportunity to Submit Proposals for the Therapeutics for Rare and Neglected Diseases (TRND) Program

Notice Number: NOT-TR-12-007

Release Date: July 3, 2012
Open Dates: August 1 to September 30, 2012

National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)

The National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation, intends to publish an opportunity for research on the following:  The NCATS Therapeutics for Rare and Neglected Diseases (TRND) program performs preclinical and early clinical development of new drugs for rare and neglected diseases, and develops new technologies and paradigms to improve the efficiency of therapeutic development for these diseases.  The operational model of TRND is collaboration between intramural NCATS drug development scientists and partners having promising leads and disease/target knowledge but lacking the expertise or resources to develop these projects into clinical stage programs attractive to biopharmaceutical or other suitable organizations.  TRND is establishing collaborations with researchers in the public and private sectors to together “de-risk” Rare and Neglected disease drug development projects by accomplishing lead optimization through an FDA Investigational New Drug (IND) application and, when needed, proof-of-concept human studies. 

This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. 

This announcement for collaboration will not use NIH activity codes. Details of the opportunity are below.

Research Initiative Details

TRND collaborative projects will be initiated at any stage during preclinical development. Projects of interest will be at one of the following stages:

• Lead optimization including clear structure-activity relationships (SAR) in at least two structurally distinct chemical series or well defined biological lead, reproducible activity in primary and orthogonal assays, efficacy in an accepted animal model (or when not available, cellular model) of the disease, and initial indications of favorable Absorption, Distribution, Metabolism, and Excretion (ADME) properties
  

• High-quality New Molecular Entity (NME) lead(s) with clear efficacy, good DMPK properties, and initial non-GLP safety studies demonstrating absence of gross toxicities
  

• NME clinical candidates with incomplete IND-enabling PK/PD/toxicology/formulation studies or
  a drug previously approved for another indication by FDA with efficacy in an animal (or when not available, cellular) model of a rare or neglected disease, making it a candidate for repurposing but in need of formulation, dose-finding, disease-specific toxicology, or other studies to allow clinical testing to commence.

The TRND program will partner with academic laboratories, not-for-profit organizations, and for-profit companies.  Foreign organizations may also apply. Applications are made through the online grants management website, ProposalCentral (https://proposalcentral.altum.com/). Submitted research applications will be reviewed for scientific merit and technical feasibility, as well as program balance and availability of resources.  Successful applicants will collaborate with TRND to create and implement a therapeutic development project plan.  Note this is not a grant or contract program; no extramural funding will be provided.

For more information about the TRND program, including deadlines for current or upcoming opportunities, please visit the TRND webpage at http://trnd.nih.gov.

The application deadline for the current cycle of the program is September 30, 2012.

Please direct all inquiries to:

Andre M. Pilon, PhD
Division of Preclinical Innovation (DPI)
National Center for Advancing Translational Sciences (NCATS)
National Institutes of Health [c]
P: 301-827-2746
F: 301-827-2534